User profiles for Irja Lutsar

Irja Lutsar

University of Tartu
Verified email at ut.ee
Cited by 9549

Antibiotic pharmacodynamics in cerebrospinal fluid

I Lutsar, GH McCracken Jr, IR Friedland - Clinical Infectious Diseases, 1998 - JSTOR
The term antibiotic pharmacodynamics encompasses the relation between drug concentrations
at the site of infection and the antibacterial effect. Knowledge of the pharmacodynamic …

[HTML][HTML] Discovery and development of safe-in-man broad-spectrum antiviral agents

…, V Oksenych, M Bjørås, K Telling, I Lutsar… - International Journal of …, 2020 - Elsevier
Viral diseases are one of the leading causes of morbidity and mortality in the world. Virus-specific
vaccines and antiviral drugs are the most powerful tools to combat viral diseases. …

Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat?

…, U Heininger, M Knuf, I Lutsar… - The Pediatric …, 2012 - europepmc.org
Community-acquired pneumonia (CAP) is a common cause of morbidity among children in
developed countries and accounts for an incidence of 10-40 cases per 1000 children in the …

Voriconazole treatment for less-common, emerging, or refractory fungal infections

…, G Just-Nübling, HT Schlamm, I Lutsar… - Clinical Infectious …, 2003 - academic.oup.com
Treatments for invasive fungal infections remain unsatisfactory. We evaluated the efficacy,
tolerability, and safety of voriconazole as salvage treatment for 273 patients with refractory …

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

TJ Walsh, I Lutsar, T Driscoll, B Dupont… - The Pediatric …, 2002 - journals.lww.com
Objective. To describe the safety and efficacy of voriconazole in children treated within the
compassionate release program. Methods. Children received voriconazole on a …

Improved outcome in central nervous system aspergillosis, using voriconazole treatment

…, L Corey, T Driscoll, OA Cornely, U Schuler, I Lutsar… - Blood, 2005 - ashpublications.org
The mortality of central nervous system (CNS) aspergillosis approaches 100%, requiring
improved therapies. Voriconazole gives superior efficacy and survival in invasive aspergillosis, …

Infections Due to Aspergillus terreus: A Multicenter Retrospective Analysis of 83 Cases

…, DP Kontoyiannis, JR Perfect, I Lutsar… - Clinical Infectious …, 2004 - academic.oup.com
Current in vitro and in vivo data indicate that invasive aspergillosis due to Aspergillus terreus
is resistant to treatment with amphotericin B. Because little clinical data are available to …

Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration

…, AJ Vora, AC Arrieta, J Blumer, I Lutsar… - Antimicrobial agents …, 2004 - Am Soc Microbiol
We conducted a multicenter study of the safety, tolerability, and plasma pharmacokinetics of
the parenteral formulation of voriconazole in immunocompromised pediatric patients (2 to …

Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients

…, C Arteaga, D Ellis, CH Heath, I Lutsar… - Antimicrobial agents …, 2008 - Am Soc Microbiol
The efficacy of voriconazole in 107 patients with scedosporiosis was analyzed. Principal
infection sites were the lungs/sinuses (24%), central nervous system (CNS) (20%), and bone (18…

Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients

I Lutsar, S Roffey, P Troke - Clinical infectious diseases, 2003 - academic.oup.com
We characterized voriconazole concentrations in the cerebrospinal fluid (CSF) of immunocompetent
guinea pigs and patients with invasive fungal infections. In animals, after receipt of …